prednisone has been researched along with Adverse Drug Event in 76 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Current myasthenia gravis guidelines recommend the use of azathioprine as first-line steroid sparing agent." | 9.41 | Methotrexate in generalized myasthenia gravis: a systematic review. ( Adiao, KJB; Prado, MB, 2023) |
| "Several trials comparing the efficacy of standard melphalan and prednisone (MP) therapy with MP plus thalidomide (MPT) in elderly patients with multiple myeloma (MM) have been reported, with inconsistent results." | 9.15 | A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant. ( Balleari, E; Buda, G; Consoli, U; Di Renzo, N; Ferrara, R; Fragasso, A; Lazzaro, A; Marcheselli, R; Masini, L; Morabito, F; Musto, P; Neri, S; Pastorini, A; Polimeno, G; Quarta, G; Sacchi, S; Vigliotti, ML; Zoboli, A, 2011) |
| " Oral melphalan, prednisone, and thalidomide have been regarded as the standard of care in elderly multiple myeloma patients." | 9.12 | Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. ( Ambrosini, MT; Boccadoro, M; Bringhen, S; Ciccone, G; Corradini, P; Crippa, C; Di Raimondo, F; Falco, P; Falcone, A; Foà, R; Gay, F; Giuliani, N; Knight, R; Musto, P; Omedè, P; Palumbo, A; Petrucci, MT; Zeldis, JB, 2007) |
| " to July 31st, 2022 with Vasculitis Foundation Canada about the patient experience and SE of prednisone." | 8.31 | A Canadian vasculitis patient-driven survey to highlight which prednisone-related side effects matter the most. ( Pagnoux, C; Stewart, J; Yardimci, GK, 2023) |
| " Neutropenia subsided completely after withdrawal of prednisone and thienopyridine in all cases and the blood cell formula normalized within 3 weeks." | 7.74 | Neutropenia in patients treated with thienopyridines and high-dose oral prednisone after percutaneous coronary interventions. ( Brunelleschi, S; Feola, M; Ferrero, V; Ribichini, F; Rognoni, A; Vacca, G; Vassanelli, C, 2007) |
| "Current myasthenia gravis guidelines recommend the use of azathioprine as first-line steroid sparing agent." | 5.41 | Methotrexate in generalized myasthenia gravis: a systematic review. ( Adiao, KJB; Prado, MB, 2023) |
| "The superiority of a chemotherapy with doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone (ACVBP) in comparison with cyclophosphamide, doxorubicin, vincristin and prednisone plus radiotherapy for young patients with localized diffuse large B-cell lymphoma (DLBCL) was previously demonstrated." | 5.17 | Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). ( Anglaret, B; Bologna, S; Bonnet, C; Bordessoule, D; Brière, J; Casasnovas, O; Christian, B; Coiffier, B; Connerotte, T; Delarue, R; Fabiani, B; Fermé, C; Fruchart, C; Haioun, C; Ketterer, N; Morschhauser, F; Récher, C; Soussain, C; Thieblemont, C; Tilly, H, 2013) |
| "Several trials comparing the efficacy of standard melphalan and prednisone (MP) therapy with MP plus thalidomide (MPT) in elderly patients with multiple myeloma (MM) have been reported, with inconsistent results." | 5.15 | A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant. ( Balleari, E; Buda, G; Consoli, U; Di Renzo, N; Ferrara, R; Fragasso, A; Lazzaro, A; Marcheselli, R; Masini, L; Morabito, F; Musto, P; Neri, S; Pastorini, A; Polimeno, G; Quarta, G; Sacchi, S; Vigliotti, ML; Zoboli, A, 2011) |
| " Oral melphalan, prednisone, and thalidomide have been regarded as the standard of care in elderly multiple myeloma patients." | 5.12 | Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. ( Ambrosini, MT; Boccadoro, M; Bringhen, S; Ciccone, G; Corradini, P; Crippa, C; Di Raimondo, F; Falco, P; Falcone, A; Foà, R; Gay, F; Giuliani, N; Knight, R; Musto, P; Omedè, P; Palumbo, A; Petrucci, MT; Zeldis, JB, 2007) |
| " to July 31st, 2022 with Vasculitis Foundation Canada about the patient experience and SE of prednisone." | 4.31 | A Canadian vasculitis patient-driven survey to highlight which prednisone-related side effects matter the most. ( Pagnoux, C; Stewart, J; Yardimci, GK, 2023) |
| "This study highlights the impact short term anti-inflammatory doses of prednisone or prednisolone have on dog behaviour and confirms our hypothesis that by day 14, 90% of dogs experienced one or more behaviour changes, with polyuria and polydipsia most commonly reported." | 4.31 | Perception and usage of short-term prednisone and prednisolone in dogs. ( Gober, M; Hillier, A, 2023) |
| " The most important reported side effect was weight gain, associated with increased appetite among prednisone users (as monotherapy as well as in combination with other drugs)." | 3.96 | Ranking Self-reported Gastrointestinal Side Effects of Pharmacotherapy in Sarcoidosis. ( Bast, A; de Jong, SMG; Drent, M; Ebner, NM; Elfferich, MDP; Jessurun, NT; Lewis, EDO; Proesmans, VLJ, 2020) |
| " Neutropenia subsided completely after withdrawal of prednisone and thienopyridine in all cases and the blood cell formula normalized within 3 weeks." | 3.74 | Neutropenia in patients treated with thienopyridines and high-dose oral prednisone after percutaneous coronary interventions. ( Brunelleschi, S; Feola, M; Ferrero, V; Ribichini, F; Rognoni, A; Vacca, G; Vassanelli, C, 2007) |
| "Childhood-onset systemic lupus erythematosus (cSLE) is an autoimmune disease that results in significant damage and often needs more aggressive treatment." | 3.01 | Childhood-onset systemic lupus erythematosus: characteristics and the prospect of glucocorticoid pulse therapy. ( Guo, L; Liu, C; Liu, J; Pan, L; Punaro, M; Yang, S, 2023) |
| " Two serious adverse events occurred, both in the placebo group (inguinal hernia and severe deterioration of cluster headache)." | 3.01 | Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial. ( Böger, A; Diener, HC; Freilinger, T; Gaul, C; Holle, D; Jansen, JP; Jürgens, TP; Katsarava, Z; Kaube, H; Kleinschnitz, C; Kraya, T; Nägel, S; Obermann, M; Ose, C; Scherag, A; Sonuc, N; Storch, P; Straube, A, 2021) |
| "Niclosamide has preclinical activity against a wide range of cancers." | 3.01 | Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer. ( Agarwal, N; Dall'Era, M; Evans, CP; Gao, AC; Lara, PN; Liu, C; Pan, CX; Parikh, M; Robles, D; Wu, CY, 2021) |
| "Metformin thus seems to be a promising drug for preventing metabolic side effects during systemic glucocorticoid treatment." | 2.84 | Metformin prevents metabolic side effects during systemic glucocorticoid treatment. ( Bally, M; Christ-Crain, M; Korbonits, M; Meyer, S; Müller, B; Nigro, N; Pernicova, I; Schuetz, P; Seelig, E; Timper, K, 2017) |
| "Mitoxantrone was approved for use in metastatic castrate-resistant prostate cancer (mCRPC) based on pain palliation without observed survival benefit in a small phase III trial in 1996." | 2.80 | Comparative effectiveness of mitoxantrone plus prednisone versus prednisone alone in metastatic castrate-resistant prostate cancer after docetaxel failure. ( Basch, E; Corty, RW; Dusetzina, SB; Green, AK; Meeneghan, M; Milowsky, MI; Reeder-Hayes, KE; Wood, WA, 2015) |
| "The causes of death were Hodgkin's lymphoma in 36 patients, second neoplasms in 12, cardiorespiratory diseases in 4, pulmonary diseases in 2, and unknown in 6." | 2.72 | MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors. ( Broglia, C; Cavanna, L; Chisesi, T; Corazza, GR; Corbella, F; Federico, M; Gobbi, PG; Iannitto, E; La Sala, A; Levis, A; Molica, S; Pavone, V; Sacchi, S; Valentino, F, 2006) |
| " Nevertheless, glucocorticoid administration, in long-term especially, is also seen critically because of its potential adverse conditions." | 2.61 | New concepts to reduce glucocorticoid toxicity. ( Alten, R; Mischkewitz, M, 2019) |
| "Drug-induced weight gain is a profound side effect of numerous commonly used medications." | 1.72 | Drug-induced weight gain in the last 10 years: a descriptive study. ( Ahmed, NJ; Alahmari, A; Almalki, ZS; Alshehri, AM, 2022) |
| "To describe the frequency and severity of parent-reported medication side effects (SEs) in children with juvenile idiopathic arthritis (JIA) relative to physician-reported actionable adverse events (AEs), and to assess their impact on health-related quality of life (HRQoL)." | 1.72 | Parent-Reported Medication Side Effects and Their Impact on Health-Related Quality of Life in Children With Juvenile Idiopathic Arthritis. ( Batthish, M; Berard, RA; Bruns, A; Cabral, DA; Chédeville, G; Duffy, CM; Gerhold, K; Gerschman, T; Guzman, J; McGuire, K; Proulx-Gauthier, JP; Rumsey, DG; Schmeling, H; Shiff, NJ; Soon, G; Tucker, LB, 2022) |
| "There are limited data on treatment patterns, adverse events (AEs), and economic burden in younger, commercially insured patients treated for mantle cell lymphoma (MCL)." | 1.51 | Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States. ( Burudpakdee, C; Kabadi, SM; Near, A; Wada, K, 2019) |
| "A moderate dose-response relationship was found between the long-term use of OCS monotherapy and the risk of developing complications in noninfectious intermediate, posterior, or panuveitis patients." | 1.51 | Oral corticosteroid exposure and increased risk of related complications in patients with noninfectious intermediate, posterior, or panuveitis: Real-world data analysis. ( Chirikov, VV; Kwon, Y; Patel, D; Shah, R, 2019) |
| "However, an association between ITP and influenza vaccination has not been firmly proven yet." | 1.51 | Epistaxis and gross haematuria with severe thrombocytopaenia associated with influenza vaccination. ( Abro, C; Almohammadi, A; Hrinczenko, B; Lundin, MS, 2019) |
| "Ketoconazole (KT) is a broad-spectrum antifungal agent whose pharmacological activity is based on the capability to interfere with steroid biosynthesis through an interaction with fungal cytochrome P-450 enzymes and thereby avoiding the formation of fungal walls." | 1.35 | Prednisone reduces ketoconazole-induced skeletal defects in rat fetuses. ( Amaral, VC; Nunes, GP, 2009) |
| "The dose-dense CHOP-14 regimen is efficient and safe in elderly patients with diffuse large B-cell lymphoma (DLBCL)." | 1.34 | Feasibility, efficacy and safety of CHOP-14 in elderly patients with very high-risk diffuse large B-cell lymphoma. ( de Nully Brown, P; Hansen, M; Jurlander, J; Tholstrup, D, 2007) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| "Patients with other causes of acute pancreatitis or chronic pancreatitis were excluded from the analysis." | 1.32 | Are drugs a risk factor of post-ERCP pancreatitis? ( Bauret, P; Berthier, E; Blanc, F; Blayac, JP; Fabbro-Peray, P; Hanslik, B; Hillaire-Buys, D; Larrey, D; Melki, M; Pageaux, GP; Perney, P; Roques, V, 2003) |
| "Nausea was usually precipitated by the odor of the clinic and similar odors elsewhere also caused nausea." | 1.26 | Pretreatment nausea in cancer chemotherapy: a conditioned response? ( Carli, T; Curtis, GC; Kleinman, PD; Nesse, RM, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (26.32) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (14.47) | 29.6817 |
| 2010's | 33 (43.42) | 24.3611 |
| 2020's | 12 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Pedersen, JM | 1 |
| Matsson, P | 1 |
| Bergström, CA | 1 |
| Norinder, U | 1 |
| Hoogstraate, J | 1 |
| Artursson, P | 1 |
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Saad, F | 1 |
| Efstathiou, E | 1 |
| Attard, G | 1 |
| Flaig, TW | 1 |
| Franke, F | 1 |
| Goodman, OB | 1 |
| Oudard, S | 1 |
| Steuber, T | 1 |
| Suzuki, H | 1 |
| Wu, D | 1 |
| Yeruva, K | 1 |
| De Porre, P | 1 |
| Brookman-May, S | 1 |
| Li, S | 2 |
| Li, J | 1 |
| Thomas, S | 1 |
| Bevans, KB | 1 |
| Mundle, SD | 1 |
| McCarthy, SA | 1 |
| Rathkopf, DE | 1 |
| Huynh, LM | 1 |
| Bonebrake, BT | 1 |
| DiMaio, DJ | 1 |
| Baine, MJ | 1 |
| Teply, BA | 1 |
| Ahmed, NJ | 1 |
| Alshehri, AM | 1 |
| Almalki, ZS | 1 |
| Alahmari, A | 1 |
| Prado, MB | 1 |
| Adiao, KJB | 1 |
| Yardimci, GK | 1 |
| Pagnoux, C | 1 |
| Stewart, J | 1 |
| Gober, M | 1 |
| Hillier, A | 1 |
| Pan, L | 1 |
| Liu, J | 1 |
| Liu, C | 2 |
| Guo, L | 1 |
| Punaro, M | 1 |
| Yang, S | 1 |
| Kabadi, SM | 1 |
| Near, A | 1 |
| Wada, K | 1 |
| Burudpakdee, C | 1 |
| Navarro-Perea, C | 1 |
| Garcia-Gonzalez, J | 1 |
| Perez-Blazquez, E | 1 |
| Drent, M | 1 |
| Proesmans, VLJ | 1 |
| Elfferich, MDP | 1 |
| Jessurun, NT | 1 |
| de Jong, SMG | 1 |
| Ebner, NM | 1 |
| Lewis, EDO | 1 |
| Bast, A | 1 |
| De Filippo, M | 1 |
| Clark, E | 1 |
| Fillard, A | 1 |
| Diaferio, L | 1 |
| Caimmi, D | 1 |
| Obermann, M | 1 |
| Nägel, S | 1 |
| Ose, C | 1 |
| Sonuc, N | 1 |
| Scherag, A | 1 |
| Storch, P | 1 |
| Gaul, C | 2 |
| Böger, A | 1 |
| Kraya, T | 2 |
| Jansen, JP | 1 |
| Straube, A | 1 |
| Freilinger, T | 1 |
| Kaube, H | 1 |
| Jürgens, TP | 1 |
| Diener, HC | 2 |
| Katsarava, Z | 2 |
| Kleinschnitz, C | 1 |
| Holle, D | 1 |
| Parikh, M | 1 |
| Wu, CY | 1 |
| Evans, CP | 1 |
| Dall'Era, M | 1 |
| Robles, D | 1 |
| Lara, PN | 1 |
| Agarwal, N | 1 |
| Gao, AC | 1 |
| Pan, CX | 1 |
| Chédeville, G | 1 |
| McGuire, K | 1 |
| Cabral, DA | 1 |
| Shiff, NJ | 1 |
| Rumsey, DG | 1 |
| Proulx-Gauthier, JP | 1 |
| Schmeling, H | 1 |
| Berard, RA | 1 |
| Batthish, M | 1 |
| Soon, G | 1 |
| Gerhold, K | 1 |
| Gerschman, T | 1 |
| Bruns, A | 1 |
| Duffy, CM | 1 |
| Tucker, LB | 1 |
| Guzman, J | 1 |
| Saygin, C | 1 |
| Jia, X | 1 |
| Hill, B | 1 |
| Dean, R | 1 |
| Pohlman, B | 1 |
| Smith, MR | 1 |
| Jagadeesh, D | 1 |
| Suhler, EB | 1 |
| Thorne, JE | 1 |
| Mittal, M | 1 |
| Betts, KA | 1 |
| Tari, S | 1 |
| Camez, A | 1 |
| Bao, Y | 1 |
| Joshi, A | 1 |
| Kashima, J | 1 |
| Okuma, Y | 1 |
| Shimizuguchi, R | 1 |
| Chiba, K | 1 |
| Sun, Y | 1 |
| Lee, SK | 1 |
| Oo, TH | 1 |
| Rojas-Hernandez, CM | 1 |
| Feng, SW | 1 |
| Luo, ZY | 1 |
| He, XQ | 1 |
| Liu, JH | 1 |
| Luo, DQ | 1 |
| Tantawy, AAG | 1 |
| Ebeid, FSE | 1 |
| Adly, AAM | 1 |
| El-Ghoroury, E | 1 |
| Mostafa, M | 1 |
| Clifton, D | 1 |
| Ross, M | 1 |
| O'Callaghan, C | 1 |
| Arays, R | 1 |
| Wang, P | 1 |
| Chirikov, VV | 1 |
| Shah, R | 1 |
| Kwon, Y | 1 |
| Patel, D | 1 |
| David, RJ | 1 |
| Baran, A | 1 |
| Loh, KP | 1 |
| Casulo, C | 1 |
| Barr, PM | 1 |
| Friedberg, JW | 1 |
| Reagan, PM | 1 |
| Mitchell, MA | 1 |
| Hogan, K | 1 |
| Amjadi, K | 1 |
| Alten, R | 1 |
| Mischkewitz, M | 1 |
| Turkowski, Y | 1 |
| Konnikov, N | 1 |
| Mahalingam, M | 1 |
| Almohammadi, A | 1 |
| Lundin, MS | 1 |
| Abro, C | 1 |
| Hrinczenko, B | 1 |
| Coleman, E | 1 |
| Panse, G | 1 |
| Cowper, S | 1 |
| Prebet, T | 1 |
| Gore, S | 1 |
| Leventhal, J | 1 |
| Jordheim, LP | 1 |
| Ribrag, V | 1 |
| Ghesquieres, H | 1 |
| Pallardy, S | 1 |
| Delarue, R | 2 |
| Tilly, H | 2 |
| Haioun, C | 2 |
| Jardin, F | 1 |
| Demangel, D | 1 |
| Salles, GA | 1 |
| Dumontet, C | 1 |
| Petrylak, DP | 1 |
| Vogelzang, NJ | 1 |
| Budnik, N | 1 |
| Wiechno, PJ | 1 |
| Sternberg, CN | 1 |
| Doner, K | 1 |
| Bellmunt, J | 1 |
| Burke, JM | 1 |
| de Olza, MO | 1 |
| Choudhury, A | 1 |
| Gschwend, JE | 1 |
| Kopyltsov, E | 1 |
| Flechon, A | 1 |
| Van As, N | 1 |
| Houede, N | 1 |
| Barton, D | 1 |
| Fandi, A | 1 |
| Jungnelius, U | 1 |
| de Wit, R | 1 |
| Fizazi, K | 1 |
| Green, AK | 1 |
| Corty, RW | 1 |
| Wood, WA | 1 |
| Meeneghan, M | 1 |
| Reeder-Hayes, KE | 1 |
| Basch, E | 1 |
| Milowsky, MI | 1 |
| Dusetzina, SB | 1 |
| Chan, H | 1 |
| Jackson, S | 1 |
| McLay, J | 1 |
| Knox, A | 1 |
| Lee, J | 1 |
| Wang, S | 1 |
| Issa, S | 1 |
| Bonnefoi, H | 1 |
| Grellety, T | 1 |
| Tredan, O | 1 |
| Saghatchian, M | 1 |
| Dalenc, F | 1 |
| Mailliez, A | 1 |
| L'Haridon, T | 1 |
| Cottu, P | 1 |
| Abadie-Lacourtoisie, S | 1 |
| You, B | 1 |
| Mousseau, M | 1 |
| Dauba, J | 1 |
| Del Piano, F | 1 |
| Desmoulins, I | 1 |
| Coussy, F | 1 |
| Madranges, N | 1 |
| Grenier, J | 1 |
| Bidard, FC | 1 |
| Proudhon, C | 1 |
| MacGrogan, G | 1 |
| Orsini, C | 1 |
| Pulido, M | 1 |
| Gonçalves, A | 1 |
| Seelig, E | 1 |
| Meyer, S | 1 |
| Timper, K | 1 |
| Nigro, N | 1 |
| Bally, M | 1 |
| Pernicova, I | 1 |
| Schuetz, P | 1 |
| Müller, B | 1 |
| Korbonits, M | 1 |
| Christ-Crain, M | 1 |
| Kuye, IO | 1 |
| Smith, GP | 1 |
| Ali, T | 1 |
| Srinivasan, N | 1 |
| Le, V | 1 |
| Rizvi, S | 1 |
| Rossi, D | 1 |
| Rasi, S | 1 |
| Franceschetti, S | 1 |
| Capello, D | 1 |
| Castelli, A | 1 |
| De Paoli, L | 1 |
| Ramponi, A | 1 |
| Chiappella, A | 2 |
| Pogliani, EM | 1 |
| Vitolo, U | 2 |
| Kwee, I | 1 |
| Bertoni, F | 1 |
| Conconi, A | 2 |
| Gaidano, G | 1 |
| Amaral, VC | 1 |
| Nunes, GP | 1 |
| Halbsguth, TV | 1 |
| Nogová, L | 1 |
| Mueller, H | 1 |
| Sieniawski, M | 1 |
| Eichenauer, DA | 1 |
| Schober, T | 1 |
| Nisters-Backes, H | 1 |
| Borchmann, P | 1 |
| Diehl, V | 1 |
| Engert, A | 1 |
| Josting, A | 1 |
| Zwick, C | 1 |
| Hartmann, F | 1 |
| Zeynalova, S | 1 |
| Pöschel, V | 1 |
| Nickenig, C | 1 |
| Reiser, M | 1 |
| Lengfelder, E | 1 |
| Peter, N | 1 |
| Schlimok, G | 1 |
| Schubert, J | 1 |
| Schmitz, N | 1 |
| Loeffler, M | 1 |
| Pfreundschuh, M | 1 |
| Ferreri, AJ | 1 |
| Martelli, M | 1 |
| Baldi, I | 1 |
| Balzarotti, M | 1 |
| Bottelli, C | 1 |
| Gomez, H | 1 |
| Lopez-Guillermo, A | 1 |
| Martinelli, G | 1 |
| Merli, F | 1 |
| Novero, D | 1 |
| Orsucci, L | 1 |
| Pavone, V | 2 |
| Ricardi, U | 1 |
| Storti, S | 1 |
| Gospodarowicz, MK | 1 |
| Cavalli, F | 1 |
| Sarris, AH | 1 |
| Zucca, E | 1 |
| Sacchi, S | 2 |
| Marcheselli, R | 1 |
| Lazzaro, A | 1 |
| Morabito, F | 1 |
| Fragasso, A | 1 |
| Di Renzo, N | 1 |
| Balleari, E | 1 |
| Neri, S | 1 |
| Quarta, G | 1 |
| Ferrara, R | 1 |
| Vigliotti, ML | 1 |
| Polimeno, G | 1 |
| Musto, P | 2 |
| Consoli, U | 1 |
| Zoboli, A | 1 |
| Buda, G | 1 |
| Pastorini, A | 1 |
| Masini, L | 1 |
| Rabe, K | 1 |
| Pageler, L | 1 |
| Lampl, C | 1 |
| Foerderreuther, S | 1 |
| Ketterer, N | 1 |
| Coiffier, B | 1 |
| Thieblemont, C | 1 |
| Fermé, C | 1 |
| Brière, J | 1 |
| Casasnovas, O | 1 |
| Bologna, S | 1 |
| Christian, B | 1 |
| Connerotte, T | 1 |
| Récher, C | 1 |
| Bordessoule, D | 1 |
| Fruchart, C | 1 |
| Bonnet, C | 1 |
| Morschhauser, F | 1 |
| Anglaret, B | 1 |
| Soussain, C | 1 |
| Fabiani, B | 1 |
| Shikata, H | 1 |
| Yakushijin, Y | 1 |
| Yamanouchi, J | 1 |
| Azuma, T | 1 |
| Yasukawa, M | 1 |
| LACHNIT, V | 1 |
| Perney, P | 1 |
| Berthier, E | 1 |
| Pageaux, GP | 1 |
| Hillaire-Buys, D | 1 |
| Roques, V | 1 |
| Fabbro-Peray, P | 1 |
| Melki, M | 1 |
| Hanslik, B | 1 |
| Bauret, P | 1 |
| Larrey, D | 1 |
| Blayac, JP | 1 |
| Blanc, F | 1 |
| Gobbi, PG | 1 |
| Broglia, C | 1 |
| Levis, A | 1 |
| La Sala, A | 1 |
| Valentino, F | 1 |
| Chisesi, T | 1 |
| Corbella, F | 1 |
| Cavanna, L | 1 |
| Iannitto, E | 1 |
| Molica, S | 1 |
| Corazza, GR | 1 |
| Federico, M | 1 |
| Ribichini, F | 1 |
| Ferrero, V | 1 |
| Feola, M | 1 |
| Rognoni, A | 1 |
| Brunelleschi, S | 1 |
| Vacca, G | 1 |
| Vassanelli, C | 1 |
| Case, DC | 1 |
| Desch, CE | 1 |
| Kalman, LA | 1 |
| Vongkovit, P | 1 |
| Mena, RR | 1 |
| Fridman, M | 1 |
| Allen, B | 1 |
| Tholstrup, D | 1 |
| de Nully Brown, P | 1 |
| Jurlander, J | 1 |
| Hansen, M | 1 |
| Palumbo, A | 1 |
| Falco, P | 1 |
| Corradini, P | 1 |
| Falcone, A | 1 |
| Di Raimondo, F | 1 |
| Giuliani, N | 1 |
| Crippa, C | 1 |
| Ciccone, G | 1 |
| Omedè, P | 1 |
| Ambrosini, MT | 1 |
| Gay, F | 1 |
| Bringhen, S | 1 |
| Foà, R | 1 |
| Knight, R | 1 |
| Zeldis, JB | 1 |
| Boccadoro, M | 1 |
| Petrucci, MT | 1 |
| Nesse, RM | 1 |
| Carli, T | 1 |
| Curtis, GC | 1 |
| Kleinman, PD | 1 |
| Beart, ME | 1 |
| Katz, P | 1 |
| Cutler, EA | 1 |
| Palmer, J | 1 |
| Kontras, SB | 1 |
| Demanet, JC | 1 |
| Conrad, MJ | 1 |
| Ross, LS | 1 |
| Berry, DH | 1 |
| Cline, MJ | 1 |
| May, FE | 1 |
| Stewart, RB | 1 |
| Cluff, LE | 1 |
| Simone, J | 1 |
| Lokich, JJ | 1 |
| Skarin, AT | 1 |
| DeVita, VT | 2 |
| Arseneau, JC | 2 |
| Sherins, RJ | 1 |
| Canellos, GP | 2 |
| Young, RC | 2 |
| Grundmann, E | 1 |
| Fritzsche, R | 1 |
| Sponzo, RW | 1 |
| Levin, DL | 1 |
| Schnipper, LE | 1 |
| Bonner, H | 1 |
| Johnson, RE | 1 |
| Meiring, Pde V | 1 |
| da Cruz, I | 1 |
| Gazes, PC | 1 |
| Kobylinski, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cance[NCT02257736] | Phase 3 | 982 participants (Actual) | Interventional | 2014-11-30 | Active, not recruiting | ||
| A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)[NCT00988208] | Phase 3 | 1,059 participants (Actual) | Interventional | 2009-11-11 | Completed | ||
| A Phase II Trial Evaluating the Activity of Abiraterone Acetate Plus Prednisone in Patients With a Molecular Apocrine HER2-negative Locally Advanced or Metastatic Breast Cancer[NCT01842321] | Phase 2 | 34 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| PAveMenT: Phase Ib Study of Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer[NCT04360941] | Phase 1 | 45 participants (Anticipated) | Interventional | 2020-08-11 | Recruiting | ||
| Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Melanoma, breAst or Lung Cancer Patients With Brain Metastases: the Phase II OPTIMAL Study[NCT04001725] | Phase 2 | 110 participants (Anticipated) | Interventional | 2019-10-15 | Recruiting | ||
| [NCT00284271] | Phase 2 | 65 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy With Cyclophosphamide, Procarbazine, Prednisone, Etoposide and Mitoxantrone (BrEPEM) for Older Patients With Untreated Hodgkin Lymphoma (HL)[NCT03576378] | Phase 1/Phase 2 | 41 participants (Actual) | Interventional | 2018-08-08 | Active, not recruiting | ||
| Randomized Phase II Study About the Application of Pegfilgrastim (Neulasta) at Day 2 or Day 4 Within the Treatment in Patients With Aggressive Non-Hodgkin's Lymphoma Aged 61 to 80 Years With 6 or 8 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxor[NCT00726700] | Phase 2 | 109 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| A Phase I/II Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, (BdL) for the Treatment of Patients With Relapsed Myeloma.[NCT01686386] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2010-02-28 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The OS was defined as the time from randomization to date of death from any cause. (NCT02257736)
Timeframe: Up to 5 years and 10 months
| Intervention | months (Median) |
|---|---|
| Placebo+ Abiraterone Acetate - Prednisolone | 33.71 |
| Apalutamide + Abiraterone Acetate - Prednisolone | 36.17 |
The rPFS was defined as the time from randomization to the occurrence of one of the following: 1) a participant was considered to have progressed by bone scan if - a) the first bone scan with greater than or equal to (>=) 2 new lesions compared to baseline was observed in less than (<) 12 weeks from randomization and was confirmed by a second bone scan taken >=6 weeks later showing >=2 additional new lesions (a total of >=4 new lesions compared to baseline), b) the first bone scan with >=2 new lesions compared to baseline was observed in >=12 weeks from randomization and the new lesions were verified on the next bone scan >=6 weeks later (a total of >=2 new lesions compared to baseline); 2) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. (NCT02257736)
Timeframe: Up to 3 years and 4 months
| Intervention | months (Median) |
|---|---|
| Placebo+ Abiraterone Acetate - Prednisolone | 16.59 |
| Apalutamide + Abiraterone Acetate - Prednisolone | 23.98 |
Time to chronic opioid use was defined as the time from date of randomization to the first date of opioid use. (NCT02257736)
Timeframe: Up to 5 years and 10 months
| Intervention | months (Median) |
|---|---|
| Placebo+ Abiraterone Acetate - Prednisolone | 53.26 |
| Apalutamide + Abiraterone Acetate - Prednisolone | 46.98 |
Time to initiation of cytotoxic chemotherapy was defined as the time from date of randomization to the date of initiation of cytotoxic chemotherapy. (NCT02257736)
Timeframe: Up to 5 years and 10 months
| Intervention | months (Median) |
|---|---|
| Placebo+ Abiraterone Acetate - Prednisolone | 34.23 |
| Apalutamide + Abiraterone Acetate - Prednisolone | 36.11 |
"Time to pain progression: time from randomization to first date that participant either experienced an increase by 2 points from baseline in Brief Pain Inventory Short Form (BPI-SF) worst pain intensity item (item 3) or Case Report Form (CRF) pain, observed at 2 consecutive evaluations >=4 wks apart, or initiation of chronic opioids as defined in time to chronic opioid use, whichever occurred first. BPI-SF is a self-administered questionnaire developed to assess severity of pain and impact of pain on daily functions. Item 3(worst pain intensity) asks participants to rate worst pain in prior 7-days on a 0-10 numeric rating scale, where 0 indicates No pain and 10 indicates Pain as bad as you can imagine. A lower score is better.CRF pain refers to participant's response to global pain assessment How would you rate your pain over the past 7 days?with a scale of 0(No pain) to 10(Pain as bad as you can imagine),that is systematically reported and recorded on the eCRF." (NCT02257736)
Timeframe: Up to 5 years and 10 months
| Intervention | months (Median) |
|---|---|
| Placebo+ Abiraterone Acetate - Prednisolone | 26.51 |
| Apalutamide + Abiraterone Acetate - Prednisolone | 21.82 |
Overall survival (OS) was the time from the date of randomization to the date of death from any cause. If no death was reported for a participant before the cut-off date for OS analysis, OS was censored at the last date at which the participant was alive. The median OS was calculated based on Kaplan-Meier estimates and corresponding 95% confidence interval (CI) was calculated using the method provided by Brookmeyer and Crowley. (NCT00988208)
Timeframe: From randomization until death from any cause up to the cut-off date of 13 January 2012; up to approximately 26 months
| Intervention | weeks (Median) |
|---|---|
| Docetaxel/Prednisone/Placebo (DP) | NA |
| Docetaxel/Prednisone/Lenalidomide (DPL) | 77 |
Percentage of Participants Who Received Post-Study Therapies for advanced Prostate Cancer. (NCT00988208)
Timeframe: The date when the first consent form was signed to the last date of AE data collection;up to 5 years; up to the date of the final data analysis date of 20 April 2017
| Intervention | Percentage of Participants (Number) |
|---|---|
| Docetaxel/Prednisone/Placebo (DP) | 70.8 |
| Docetaxel/Prednisone/Lenalidomide (DPL) | 69.0 |
Objective response (OR) is defined as having complete response (CR) or partial response (PR) as best overall response based on RECIST Criteria 1.1 and defines a CR = Disappearance of all target lesions except lymph nodes (LN); LN must have a decrease in the short axis to <10mm; PR = 30% decrease in sum of diameters of target lesions taking as reference the baseline sum diameters; Progressed Disease (PD) = 20% increase in sum of diameters of target lesions taking as a reference the smallest sum of diameters and an absolute increase of ≥5 mm; the appearance of ≥1 new lesions; Stable Disease (SD)= Neither shrinkage to qualify for PR nor increase to qualify for PD taking the smallest sum diameters on study as reference. For non-target lesions a CR = Disappearance of all non-target lesions and all LN must be non-pathological in size <10 mm; Non-CR/Non PD: persistence of one or more non-target lesions; PD = unequivocal progression of existing non-target lesions or appearance of new ones (NCT00988208)
Timeframe: From day 1 to data cut-off 13 January 2012; maximum time on study was approximately 26 months
| Intervention | percentage of participants (Number) |
|---|---|
| Docetaxel/Prednisone/Placebo (DP) | 24.3 |
| Docetaxel/Prednisone/Lenalidomide (DPL) | 22.1 |
PFS was the time from randomization to disease progression, or death, whatever occurred first. Progression criteria was met by analysis of target and non-target lesions as defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria. Progressive Disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters while on study or the appearance of one or more new lesions; an increase of at least 5mm as a total sum. Lymph nodes identified as target lesions (≥ 15 mm diameter in short axis) will be followed and reported by changes in diameter of short axis; or the unequivocal progression of a non-target lesion defined as an increase in the overall disease burden based on the change in non-measurable disease that is comparable in scope to the increase required to declare PD for measurable disease; Two or more new bone lesions as detected by bone scan (NCT00988208)
Timeframe: From randomization until disease progression or death from any cause; up to the cut-off date of 13 Jan 2012; maximum time on study was approximately 26 months
| Intervention | Weeks (Median) |
|---|---|
| Docetaxel/Prednisone/Placebo (DP) | 46 |
| Docetaxel/Prednisone/Lenalidomide (DPL) | 45 |
Time of Onset of Secondary Primary Malignancies was considered an event of interest (NCT00988208)
Timeframe: The date when the first consent form was signed to the last date of AE data collection; up to the date of the final data analysis date of 30 November 2016; 7 years and 19 days
| Intervention | months (Median) |
|---|---|
| Docetaxel/Prednisone/Placebo (DP) | 29.7 |
| Docetaxel/Prednisone/Lenalidomide (DPL) | 19.7 |
A TEAE is defined as any AE occurring or worsening on or after the first dose of study drug and within 28 days after the last dose of study drug. A TESAE is defined as any serious adverse event (SAE) occurring or worsening on or after the first dose of study drug and within 28 days after the last dose of study drug. Safety and severity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0; Severity of AEs were graded (including second primary malignancies) as Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life-threatening; Grade 5-Fatal; (NCT00988208)
Timeframe: From the time from of first dose of study drug administration to 28 days after the last dose of study drug and up to the data cut off date of 13 January 2012; the maximum duration of study drug was 93 weeks for DP and 90.6 weeks for DPL
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Any TEAE | Any TEAE related to lenalidomide or placebo | Any TEAE related to docetaxel/prednisone | Any severity grade 3-4 TEAE | Any serious AE (SAE) | Any SAE related to lenalidomide or placebo | Any SAE related to docetaxel/prednisone | Any AE causing discontinuation of lenalidomide/PBO | Any AE causing withdrawal of docetaxel/prednisone | Any TEAE leading to death | |
| Docetaxel/Prednisone/Lenalidomide (DPL) | 517 | 412 | 481 | 381 | 279 | 167 | 182 | 150 | 169 | 24 |
| Docetaxel/Prednisone/Placebo (DP) | 512 | 379 | 475 | 303 | 171 | 62 | 86 | 82 | 127 | 16 |
Second primary malignancies were monitored as events of interest and reported as serious adverse events throughout the course of the trial. (NCT00988208)
Timeframe: The date when the first consent form was signed to the last date of AE data collection; up to the date of the final data analysis date of 30 November 2016; 7 years and 19 days
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Invasive Secondary Primary Malignancies | Non-invasive Secondary Primary Malignancies | |
| Docetaxel/Prednisone/Lenalidomide (DPL) | 1.7 | 1.0 |
| Docetaxel/Prednisone/Placebo (DP) | 1.3 | 0.4 |
4 reviews available for prednisone and Adverse Drug Event
| Article | Year |
|---|---|
Methotrexate in generalized myasthenia gravis: a systematic review.
Topics: Azathioprine; Drug-Related Side Effects and Adverse Reactions; Humans; Immunosuppressive Agents; Met | 2023 |
Childhood-onset systemic lupus erythematosus: characteristics and the prospect of glucocorticoid pulse therapy.
Topics: Adult; Autoimmune Diseases; Child; Drug-Related Side Effects and Adverse Reactions; Glucocorticoids; | 2023 |
New concepts to reduce glucocorticoid toxicity.
Topics: Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related | 2019 |
Evaluation and treatment of the infertile man.
Topics: Chorionic Gonadotropin; Chromosome Aberrations; Chromosome Disorders; Clomiphene; Drug-Related Side | 1985 |
18 trials available for prednisone and Adverse Drug Event
| Article | Year |
|---|---|
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
Topics: Abiraterone Acetate; Aged; Androgen Receptor Antagonists; Antineoplastic Combined Chemotherapy Proto | 2021 |
Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial.
Topics: Adult; Calcium Channel Blockers; Cluster Headache; Double-Blind Method; Drug Therapy, Combination; D | 2021 |
Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug-Relat | 2021 |
Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials.
Topics: Adalimumab; Administration, Oral; Adult; Anti-Inflammatory Agents; Double-Blind Method; Drug Combina | 2017 |
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Double-Bl | 2015 |
Comparative effectiveness of mitoxantrone plus prednisone versus prednisone alone in metastatic castrate-resistant prostate cancer after docetaxel failure.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, | 2015 |
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diseas | 2016 |
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diseas | 2016 |
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diseas | 2016 |
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diseas | 2016 |
Metformin prevents metabolic side effects during systemic glucocorticoid treatment.
Topics: Adult; Aged; Anti-Inflammatory Agents; Blood Glucose; Double-Blind Method; Drug-Related Side Effects | 2017 |
Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progressi | 2010 |
Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progressi | 2010 |
Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progressi | 2010 |
Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progressi | 2010 |
Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Resp | 2011 |
First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug-Related Side Effects a | 2011 |
Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: a randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Analgesics; Anti-Inflammatory Agents; Comorbidity; Double-Blind Method; Dru | 2013 |
Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B).
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2013 |
MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 2006 |
Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2007 |
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationsh | 2007 |
Acute lymphocytic leukemia in childhood.
Topics: Asparaginase; Black People; Bone Marrow Examination; Central Nervous System Diseases; Child; Child, | 1974 |
54 other studies available for prednisone and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Bi | 2008 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities.
Topics: Aged; Antineoplastic Agents, Immunological; Carcinoma, Renal Cell; Doxycycline; Drug-Related Side Ef | 2021 |
Drug-induced weight gain in the last 10 years: a descriptive study.
Topics: Adalimumab; Adverse Drug Reaction Reporting Systems; Aripiprazole; Databases, Factual; Drug-Related | 2022 |
A Canadian vasculitis patient-driven survey to highlight which prednisone-related side effects matter the most.
Topics: Canada; Drug-Related Side Effects and Adverse Reactions; Glucocorticoids; Humans; Prednisone; Qualit | 2023 |
Perception and usage of short-term prednisone and prednisolone in dogs.
Topics: Animals; Dog Diseases; Dogs; Drug-Related Side Effects and Adverse Reactions; Hyperphagia; Perceptio | 2023 |
Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2019 |
Case report: Bilateral uveitis and papillitis secondary to treatment with pembrolizumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Drug Combinations; D | 2019 |
Ranking Self-reported Gastrointestinal Side Effects of Pharmacotherapy in Sarcoidosis.
Topics: Adult; Cross-Sectional Studies; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointes | 2020 |
Oral corticosteroids and asthma in children: Practical considerations.
Topics: Administration, Oral; Adrenal Cortex Hormones; Anti-Asthmatic Agents; Asthma; Child; Child, Preschoo | 2020 |
Parent-Reported Medication Side Effects and Their Impact on Health-Related Quality of Life in Children With Juvenile Idiopathic Arthritis.
Topics: Arthritis, Juvenile; Canada; Child; Drug-Related Side Effects and Adverse Reactions; Humans; Methotr | 2022 |
Impact of comorbidities on outcomes of elderly patients with diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Comorb | 2017 |
Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cholangiopancreatogra | 2018 |
Management of Immune-mediated Cytopenias in the Era of Cancer Immunotherapy: A Report of 4 Cases.
Topics: Anemia, Hemolytic; Antibodies, Monoclonal, Humanized; CTLA-4 Antigen; Drug-Related Side Effects and | 2018 |
Hydroxychloroquine-Induced Reversible Hypomnesis in Systemic Lupus Erythematosus.
Topics: Adult; Antirheumatic Agents; Diagnosis, Differential; Drug-Related Side Effects and Adverse Reaction | 2018 |
Influence of thiopurine methyltransferase gene polymorphism on Egyptian children with acute lymphoblastic leukaemia.
Topics: Adolescent; Alleles; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Pre | 2017 |
Psychiatric sequelae of corticosteroid use in hematology in Australia: A qualitative study.
Topics: Adrenal Cortex Hormones; Adult; Australia; Dexamethasone; Drug-Related Side Effects and Adverse Reac | 2018 |
A case of pembrolizumab-induced localized organizing pneumonia.
Topics: Antibodies, Monoclonal, Humanized; Brain; Cryptogenic Organizing Pneumonia; Drug-Related Side Effect | 2018 |
Oral corticosteroid exposure and increased risk of related complications in patients with noninfectious intermediate, posterior, or panuveitis: Real-world data analysis.
Topics: Administration, Oral; Data Analysis; Dose-Response Relationship, Drug; Drug-Related Side Effects and | 2019 |
Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2018 |
Atezolizumab-induced sarcoid-like granulomatous reaction in a patient with urothelial cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug-Related Side | 2018 |
Necrotizing Granulomas in a Patient With Psoriasis and Sarcoidosis After Adalimumab-Medication-Induced Reaction or Reactivation of Latent Disease?
Topics: Adalimumab; Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Biopsy, Needle; Combined | 2019 |
Epistaxis and gross haematuria with severe thrombocytopaenia associated with influenza vaccination.
Topics: Aged; Anti-Inflammatory Agents; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Epis | 2019 |
Lobular neutrophilic panniculitis associated with DNA methyltransferase inhibitors in the treatment of myeloid disease.
Topics: Aged; Antineoplastic Agents; Azacitidine; Diagnosis, Differential; DNA; Drug-Related Side Effects an | 2019 |
Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma.
Topics: Alcohol Oxidoreductases; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2015 |
Obese non-Hodgkin lymphoma patients tolerate full uncapped doses of chemotherapy with no increase in toxicity, and a similar survival to that seen in nonobese patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2016 |
The Use of Rituximab in the Management of Refractory Dermatomyositis.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Dermatomyositis; Drug-Related Side Effects and Advers | 2017 |
Alpha-methyldopa hepatotoxicity in pregnancy.
Topics: Adult; Anti-Inflammatory Agents; Antihypertensive Agents; Chemical and Drug Induced Liver Injury; Di | 2009 |
Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2009 |
Prednisone reduces ketoconazole-induced skeletal defects in rat fetuses.
Topics: Abnormalities, Drug-Induced; Animals; Bone and Bones; Dose-Response Relationship, Drug; Drinking; Dr | 2009 |
Analysis of chemotherapy-induced neutropenia and optimal timing for prophylactic use of G-CSF in B-cell non-Hodgkin lymphoma patients treated with R-CHOP.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
[Therapy of irritant gas poisoning].
Topics: Cardiovascular Agents; Drug-Related Side Effects and Adverse Reactions; Gas Poisoning; Irritants; Ni | 1958 |
Are drugs a risk factor of post-ERCP pancreatitis?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Cholangiopancreatography, Endoscopic Retro | 2003 |
Neutropenia in patients treated with thienopyridines and high-dose oral prednisone after percutaneous coronary interventions.
Topics: Aged; Angioplasty, Balloon, Coronary; Anti-Infective Agents; Coronary Restenosis; Drug-Related Side | 2007 |
Feasibility, efficacy and safety of CHOP-14 in elderly patients with very high-risk diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cycl | 2007 |
Pretreatment nausea in cancer chemotherapy: a conditioned response?
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Conditioning, Psycholo | 1980 |
Thrombocytopenia: mechanisms and management.
Topics: Adult; Blood Platelets; Child; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Pred | 1982 |
Hypersensitivity vasculitis.
Topics: Adrenal Cortex Hormones; Bacterial Infections; Drug-Related Side Effects and Adverse Reactions; Huma | 1982 |
Chemotherapy and possible zinc deficiency.
Topics: Child; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Prednisone; Zinc | 1977 |
[Serious complications of current treatments].
Topics: Acidosis; Adolescent; Aged; Alcoholism; Antihypertensive Agents; Aspirin; Diuretics; Drug-Related Si | 1975 |
Treatment of Hodgkin's disease.
Topics: Drug-Related Side Effects and Adverse Reactions; Female; Hodgkin Disease; Humans; Laparotomy; Male; | 1974 |
Psychiatric side effects of nonpsychiatric drugs.
Topics: Aminophylline; Analgesics; Anti-Anxiety Agents; Anti-Bacterial Agents; Anticonvulsants; Antiemetics; | 1971 |
The child with acute leukemia.
Topics: Age Factors; Asparaginase; Chickenpox; Child, Preschool; Counseling; Cyclophosphamide; Cytarabine; C | 1974 |
Editorial: Drugs and phagocytes.
Topics: Adrenal Cortex Hormones; Animals; Drug-Related Side Effects and Adverse Reactions; Humans; Infection | 1974 |
Drug use in the hospital: evaluation of determinants.
Topics: Acetaminophen; Aluminum Hydroxide; Analgesics; Antacids; Anti-Bacterial Agents; Chloral Hydrate; Dex | 1974 |
Five-drug combination chemotherapy for disseminated adenocarcinoma.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Drug | 1972 |
Intensive chemotherapy for Hodgkin's disease: long-term complications.
Topics: Antineoplastic Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; E | 1973 |
[Pathology of treated Hodgkin's disease. A retrospective study (author's transl)].
Topics: Adolescent; Adult; Age Factors; Aged; Autopsy; Child; Child, Preschool; Drug Therapy, Combination; D | 1974 |
Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy.
Topics: Adolescent; Adult; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Drug-Related S | 1972 |
To the Editor. Adverse effects from drugs.
Topics: Chlorpropamide; Digoxin; Drug-Related Side Effects and Adverse Reactions; Indomethacin; Penicillins; | 1969 |
Noncardiac surgery in cardiac patients. 1. Preoperative evaluation.
Topics: Anesthetics; Anti-Arrhythmia Agents; Anticoagulants; Antidepressive Agents; Antihypertensive Agents; | 1971 |
[Therapy related changes in leukemias].
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Arsenic; Chemical and Drug In | 1967 |